CTLA4 and neoplasm: Meanwhile, anti-CTLA-4 therapy decreased the number of Tregs in tumor tissues, and it was significantly associated with favorable clinical events, implying that Tregs may mutually affect immune checkpoint molecules in immune regulation (96).